))
ποΈ Episode 31: Semaglutide and the Eye: NAION Signal in Sight.
Manage episode 478124860 series 3659512
Content provided by Brilliant Board Review & CME, Brilliant Board Review, and CME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Brilliant Board Review & CME, Brilliant Board Review, and CME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
π§ͺ Key Insights:
Observational data links semaglutide (GLP-1 RA) to increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
Incidence: ~9β15 cases per 100,000 patient-years.
Possible mechanism: GLP-1 receptors in optic nerve ganglion cells.
No proven causality yet β retrospective study only.
𧩠Clinical Takeaway:
Risk remains very low.
Discuss with patients who have eye disease or prior NAION before initiating therapy.
Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.
Chapters
1. Semaglutide and Optic Neuropathy Link (00:00:00)
2. Higher Incidence Rates Compared to SGLT2s (00:00:45)
3. Potential Mechanism and Clinical Implications (00:01:19)
4. Weighing Benefits Against New Concerns (00:01:58)
45 episodes
Share
